10X Financial Statements From 2010 to 2024
| 1KJ Stock | EUR 14.19 0.04 0.28% |
Check 10X GENOMICS financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among 10X GENOMICS's main balance sheet or income statement drivers, such as , as well as many indicators such as . 10X financial statements analysis is a perfect complement when working with 10X GENOMICS Valuation or Volatility modules.
10X |
10X GENOMICS DL Company Shares Outstanding Analysis
10X GENOMICS's Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current 10X GENOMICS Shares Outstanding | 95.6 M |
Most of 10X GENOMICS's fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, 10X GENOMICS DL is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
| Competition |
Based on the latest financial disclosure, 10X GENOMICS DL has 95.6 M of shares currently outstending. This is 47.05% lower than that of the Healthcare sector and significantly higher than that of the Health Information Services industry. The shares outstanding for all Germany stocks is 83.28% higher than that of the company.
10X GENOMICS DL Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining 10X GENOMICS's current stock value. Our valuation model uses many indicators to compare 10X GENOMICS value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across 10X GENOMICS competition to find correlations between indicators driving 10X GENOMICS's intrinsic value. More Info.10X GENOMICS DL is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the 10X GENOMICS's earnings, one of the primary drivers of an investment's value.About 10X GENOMICS Financial Statements
10X GENOMICS stakeholders use historical fundamental indicators, such as 10X GENOMICS's revenue or net income, to determine how well the company is positioned to perform in the future. Although 10X GENOMICS investors may analyze each financial statement separately, they are all interrelated. For example, changes in 10X GENOMICS's assets and liabilities are reflected in the revenues and expenses on 10X GENOMICS's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in 10X GENOMICS DL. Please read more on our technical analysis and fundamental analysis pages.
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California. 10X GENOMICS operates under Health Information Services classification in Germany and is traded on Frankfurt Stock Exchange. It employs 852 people.
Currently Active Assets on Macroaxis
Other Information on Investing in 10X Stock
10X GENOMICS financial ratios help investors to determine whether 10X Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in 10X with respect to the benefits of owning 10X GENOMICS security.